Currently, 50% of the drugs in experimentation are biotechnological. Within a few years, eight out of 10 drugs will be b...
Genenta Science: Temferon™ for the treatment of glioblastoma
Genenta Science, a clinical-stage immuno-oncology company, has received Orphan Drug Designation (ODD) from the European ...